Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet ...
Jan 23, 2024
0
89
State and local governments across the US are grappling with a growing problem: Expensive drugs to treat diabetes and obesity are threatening to drain their health care budgets.
Jan 9, 2024
0
5
Sibling death in childhood and early adulthood is associated with an increased risk for cardiovascular disease (CVD), according to a study published online Jan. 8 in JAMA Network Open.
Jan 8, 2024
0
0
A recent study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat type 2 diabetes and obesity, can lead to a rapid improvement ...
Jan 4, 2024
0
7
The U.S. Food and Drug Administration is investigating reports of additional dangers linked to several wildly popular weight-loss drugs.
Jan 4, 2024
0
18
Managing diabetes will be a less expensive proposition for more Americans in 2024.
Jan 2, 2024
0
9
Brain health after COVID-19 is impaired, but no more than that seen for patients hospitalized for other medical conditions of similar severity, according to a study published online Dec. 28 in JAMA Network Open.
Dec 29, 2023
0
0
The U.S. Food and Drug Administration has uncovered counterfeit Ozempic shots in the legitimate U.S. drug supply chain, and is warning patients to be on their guard.
Dec 22, 2023
0
1
Wegovy, Mounjaro, Ozempic... These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?
Dec 4, 2023
0
0
Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.
Dec 4, 2023
0
0
